Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M38.9Revenue (TTM) $M11.9Net Margin (%)-155.8Altman Z-Score-3.8
Enterprise Value $M35.5EPS (TTM) $-7.0Operating Margin %-91.1Piotroski F-Score2
P/E(ttm)--Beneish M-Score-3.0Pre-tax Margin (%)-155.8Higher ROA y-yN
Price/Book0.410-y EBITDA Growth Rate %-8.8Quick Ratio1.7Cash flow > EarningsY
Price/Sales0.85-y EBITDA Growth Rate %14.1Current Ratio2.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-36.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-55.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M9.8ROIC % (ttm)-37.3Gross Margin Increase y-yN

Gurus Latest Trades with KOOL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
KOOLKen Fisher 2011-09-30 Sold Out -0.0001%$24 - $42.6
($34.42)
$ 4.00-88%Sold Out0
KOOLKen Fisher 2011-06-30 Buy $38.2 - $49.4
($43.87)
$ 4.00-91%New holding1,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

KOOL is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


KOOL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Harris KennethFormer Director/Officer 2015-11-10Sell4,043$12-66.67view
Harris KennethFormer Director/Officer 2015-11-03Sell526$12-66.67view
Harris KennethFormer Director/Officer 2015-10-29Sell432$12-66.67view
Plavan Matthew TFormer CEO 2015-09-02Sell864$13.6-70.59view
Rhein Denis MichaelDirector 2014-12-01Sell0$0-70.59view
ENGLE J MELVILLEChairman & CEO 2011-03-10Buy1,125$46-91.3view
ARTILES JORGEVP, Quality/Regulatory Affairs 2010-01-13Buy5$48.8-91.8view
ENGLE J MELVILLECEO 2009-09-25Buy1,250$45.6-91.23view
MCENANY PATRICK JDirector 2009-05-19Buy313$46.4-91.38view
ENGLE J MELVILLECEO 2009-05-12Buy1,250$44-90.91view

Quarterly/Annual Reports about KOOL:

News about KOOL:

Articles On GuruFocus.com
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 05 2009 

More From Other Websites
Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: 2016 By the Numbers : September 28, 2016 Sep 28 2016
Cesca Therapeutics to Present & Exhibit at the ISCT North America 2016 Regional Meeting Sep 27 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits Sep 26 2016
CESCA THERAPEUTICS INC. Financials Sep 24 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Sep 21 2016
Edited Transcript of KOOL earnings conference call or presentation 20-Sep-16 9:00pm GMT Sep 20 2016
CESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL 2016 YEAR END RESULTS Sep 20 2016
Cesca Therapeutics Reports Fourth Quarter and Fiscal 2016 Year End Results Sep 20 2016
Q4 2016 Cesca Therapeutics Inc Earnings Release - After Market Close Sep 20 2016
CESCA THERAPEUTICS TO REPORT FISCAL FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS AND PROVIDE... Sep 19 2016
CESCA THERAPEUTICS GRANTED TWO PATENTS FOR RAPID INFUSION OF AUTOLOGOUS BONE MARROW DERIVED STEM... Sep 19 2016
Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem... Sep 19 2016
Cesca Therapeutics to Report Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provide... Sep 16 2016
Cesca Therapeutics to Present at the 18th Annual Rodman & Renshaw® Global Investment Conference Sep 08 2016
Arcadia Biosciences Names New Chief Financial Officer Sep 08 2016
Chinese stem-cell research company takes control of Rancho Cordova's Cesca Therapeutics Aug 26 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Aug 25 2016
CESCA THERAPEUTICS ANNOUNCES CONVERSION OF $12.5 MILLION IN SENIOR SECURED DEBT TO EQUITY Aug 25 2016
Cesca Therapeutics Announces Conversion of $12.5 Million in Senior Secured Debt to Equity Aug 24 2016
Cesca Therapeutics raises $2.5 million in private placement of stock Aug 04 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)